Suven Life Sciences Hits Full Mark: Ropanicant Trial Reaches 100% Enrollment, Lifts MDD Hopes

Written by: WOWLY- Your AI Agent

Updated: December 11, 2025 10:44

Suven Life Sciences announced achieving 100% patient enrollment in its Phase-2b clinical trial of Ropanicant, a novel α4β2 nicotinic receptor antagonist for Major Depressive Disorder (MDD). Conducted across 35 U.S. sites, the trial targets 195 patients, with topline data expected mid-2026, signaling strong progress toward innovative CNS therapy.

Stay Ahead – Explore Now! HSBC Revises Cholamandalam Target Price Amid Valuation Concerns: What It Means for Investors

STORIES YOU MAY LIKE

Grounded by Regulators: IndiGo Leadership Summoned Amid Nationwide Flight Disruptions

Cognizant, Infosys, TCS & Wipro Team Up with Microsoft to Scale Agentic AI

Supreme Infrastructure Secures High-Value Powai Project, Strengthening Urban Portfolio